IDH1/2 mutations, found in approximately 39% of chondrosarcoma cases, are strongly correlated with poor survival, larger tumor size, higher grade, and increased relapse risk, positioning them as crucial prognostic indicators. Here, IDH1 is linked to chondrosarcoma.